Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

CD79B mutations in primary vitreoretinal lymphoma: Diagnostic and prognostic potential.

Yonese I, Takase H, Yoshimori M, Onozawa E, Tsuzura A, Miki T, Mochizuki M, Miura O, Arai A.

Eur J Haematol. 2019 Feb;102(2):191-196. doi: 10.1111/ejh.13191. Epub 2018 Nov 23.

PMID:
30390359
2.

STAT3 is constitutively activated in chronic active Epstein-Barr virus infection and can be a therapeutic target.

Onozawa E, Shibayama H, Takada H, Imadome KI, Aoki S, Yoshimori M, Shimizu N, Fujiwara S, Koyama T, Miura O, Arai A.

Oncotarget. 2018 Jul 24;9(57):31077-31089. doi: 10.18632/oncotarget.25780. eCollection 2018 Jul 24.

3.

[Cerebrospinal fluid findings in chronic active Epstein-Barr virus infection with central nervous system involvement].

Yoshimori M, Imadome KI, Tomii S, Yamamoto K, Miura O, Arai A.

Rinsho Ketsueki. 2018;59(4):367-372. doi: 10.11406/rinketsu.59.367. Japanese.

PMID:
29743394
4.

Evaluation of Endovenous Laser Ablation for Varicose Veins Using a Computer Simulation Model (Secondary publication).

Hazama H, Yoshimori M, Honda N, Awazu K.

Laser Ther. 2017 Dec 31;26(4):282-287. doi: 10.5978/islsm.17-RE-03. Review.

5.

Correction: EBV induces persistent NF-κB activation and contributes to survival of EBV-positive neoplastic T- or NK-cells.

Takada H, Imadome KI, Shibayama H, Yoshimori M, Wang L, Saitoh Y, Uota S, Yamaoka S, Koyama T, Shimizu N, Yamamoto K, Fujiwara S, Miura O, Arai A.

PLoS One. 2017 Aug 1;12(8):e0182682. doi: 10.1371/journal.pone.0182682. eCollection 2017.

6.

EBV induces persistent NF-κB activation and contributes to survival of EBV-positive neoplastic T- or NK-cells.

Takada H, Imadome KI, Shibayama H, Yoshimori M, Wang L, Saitoh Y, Uota S, Yamaoka S, Koyama T, Shimizu N, Yamamoto K, Fujiwara S, Miura O, Arai A.

PLoS One. 2017 Mar 27;12(3):e0174136. doi: 10.1371/journal.pone.0174136. eCollection 2017. Erratum in: PLoS One. 2017 Aug 1;12 (8):e0182682.

7.

State dependence of climatic instability over the past 720,000 years from Antarctic ice cores and climate modeling.

Dome Fuji Ice Core Project Members:, Kawamura K, Abe-Ouchi A, Motoyama H, Ageta Y, Aoki S, Azuma N, Fujii Y, Fujita K, Fujita S, Fukui K, Furukawa T, Furusaki A, Goto-Azuma K, Greve R, Hirabayashi M, Hondoh T, Hori A, Horikawa S, Horiuchi K, Igarashi M, Iizuka Y, Kameda T, Kanda H, Kohno M, Kuramoto T, Matsushi Y, Miyahara M, Miyake T, Miyamoto A, Nagashima Y, Nakayama Y, Nakazawa T, Nakazawa F, Nishio F, Obinata I, Ohgaito R, Oka A, Okuno J, Okuyama J, Oyabu I, Parrenin F, Pattyn F, Saito F, Saito T, Saito T, Sakurai T, Sasa K, Seddik H, Shibata Y, Shinbori K, Suzuki K, Suzuki T, Takahashi A, Takahashi K, Takahashi S, Takata M, Tanaka Y, Uemura R, Watanabe G, Watanabe O, Yamasaki T, Yokoyama K, Yoshimori M, Yoshimoto T.

Sci Adv. 2017 Feb 8;3(2):e1600446. doi: 10.1126/sciadv.1600446. eCollection 2017 Feb.

8.

P-glycoprotein is expressed and causes resistance to chemotherapy in EBV-positive T-cell lymphoproliferative diseases.

Yoshimori M, Takada H, Imadome K, Kurata M, Yamamoto K, Koyama T, Shimizu N, Fujiwara S, Miura O, Arai A.

Cancer Med. 2015 Oct;4(10):1494-504. doi: 10.1002/cam4.494. Epub 2015 Jul 8.

9.

L-Asparaginase monotherapy for EBV-positive T/NK lymphoproliferative diseases: A pilot Study.

Jinta M, Imadome K, Komatsu H, Yoshimori M, Kurata M, Fujiwara S, Miura O, Arai A.

J Med Dent Sci. 2015 Mar 30;62(1):1-9. doi: 10.11480/620101.

PMID:
26111530
10.

CD137 expression is induced by Epstein-Barr virus infection through LMP1 in T or NK cells and mediates survival promoting signals.

Yoshimori M, Imadome K, Komatsu H, Wang L, Saitoh Y, Yamaoka S, Fukuda T, Kurata M, Koyama T, Shimizu N, Fujiwara S, Miura O, Arai A.

PLoS One. 2014 Nov 19;9(11):e112564. doi: 10.1371/journal.pone.0112564. eCollection 2014.

11.

IFN production ability and healthy ageing: mixed model analysis of a 24 year longitudinal study in Japan.

Uno K, Yagi K, Yoshimori M, Tanigawa M, Yoshikawa T, Fujita S.

BMJ Open. 2013 Jan 11;3(1). pii: e002113. doi: 10.1136/bmjopen-2012-002113.

12.

The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation.

Imai Y, Yoshimori M, Fukuda K, Yamagishi H, Ueda Y.

Oncol Rep. 2012 Jun;27(6):1703-9. doi: 10.3892/or.2012.1724. Epub 2012 Mar 15.

PMID:
22426819
13.

Clinical features of adult-onset chronic active Epstein-Barr virus infection: a retrospective analysis.

Arai A, Imadome KI, Watanabe Y, Yoshimori M, Koyama T, Kawaguchi T, Nakaseko C, Fujiwara S, Miura O.

Int J Hematol. 2011 May;93(5):602-609. doi: 10.1007/s12185-011-0831-x. Epub 2011 Apr 14.

PMID:
21491104
14.

The effects of methyl mercaptan on epithelial cell growth and proliferation.

Setoguchi T, Machigashira M, Yamamoto M, Yotsumoto Y, Yoshimori M, Izumi Y, Yaegaki K.

Int Dent J. 2002 Jun;52 Suppl 3:241-6.

PMID:
12090461
15.

Instability of glacial climate in a model of the ocean- atmosphere-cryosphere system.

Schmittner A, Yoshimori M, Weaver AJ.

Science. 2002 Feb 22;295(5559):1489-93. Epub 2002 Jan 31.

16.

Prognosis of hepatocellular carcinoma with no tumor stain treated by percutaneous ethanol injection.

Ueno H, Okada S, Okusaka T, Ikeda M, Tanaka N, Sakamoto M, Yoshimori M.

Hepatogastroenterology. 2001 Sep-Oct;48(41):1430-4.

PMID:
11677980
17.

Increase of R5 HIV-1 infection and CCR5 expression in T cells treated with high concentrations of CXCR4 antagonists and SDF-1.

Gotoh K, Yoshimori M, Kanbara K, Tamamura H, Kanamoto T, Mochizuki K, Fujii N, Nakashima H.

J Infect Chemother. 2001 Mar;7(1):28-36.

PMID:
11406754
18.

Biological and genetic characterization of a human immunodeficiency virus strain resistant to CXCR4 antagonist T134.

Kanbara K, Sato S, Tanuma J, Tamamura H, Gotoh K, Yoshimori M, Kanamoto T, Kitano M, Fujii N, Nakashima H.

AIDS Res Hum Retroviruses. 2001 May 1;17(7):615-22.

PMID:
11375057
19.

Anti-human immunodeficiency virus activity of YK-FH312 (a betulinic acid derivative), a novel compound blocking viral maturation.

Kanamoto T, Kashiwada Y, Kanbara K, Gotoh K, Yoshimori M, Goto T, Sano K, Nakashima H.

Antimicrob Agents Chemother. 2001 Apr;45(4):1225-30.

20.

A phase II study of sequential methotrexate and 5-fluorouracil in metastatic pancreatic cancer.

Ikeda M, Okada S, Ueno H, Okusaka T, Tanaka N, Kuriyama H, Yoshimori M.

Hepatogastroenterology. 2000 May-Jun;47(33):862-5.

PMID:
10919048
21.

Evaluation of the therapeutic effect of transcatheter arterial embolization for hepatocellular carcinoma.

Okusaka T, Okada S, Ueno H, Ikeda M, Yoshimori M, Shimada K, Yamamoto J, Kosuge T, Yamasaki S, Iwata R, Furukawa H, Moriyama N, Sakamoto M, Hirohashi S.

Oncology. 2000 May;58(4):293-9.

PMID:
10838494
22.

5-fluorouracil continuous infusion combined with cisplatin for advanced pancreatic cancer: a Japanese Cooperative Study.

Nose H, Okada S, Okusaka T, Furuse J, Yoshino M, Ogoshi K, Kato T, Miyaji M, Hoshino M, Ariyama J, Suyama M, Karasawa E, Yoshimori M.

Hepatogastroenterology. 1999 Nov-Dec;46(30):3244-8.

PMID:
10626195
23.

Clinicopathological features in misdiagnosed pancreatic carcinoma.

Nagahama H, Okada S, Okusaka T, Ishii H, Ikeda M, Nakasuka H, Yoshimori M.

Hepatogastroenterology. 1999 Sep-Oct;46(29):2983-5.

PMID:
10576387
24.

A case of pancreatic cancer achieving symptomatic improvement with systemic chemotherapy.

Kosakamoto H, Okada S, Ueno H, Okusaka T, Ikeda M, Tanaka N, Yoshimori M, Matsuno Y.

Hepatogastroenterology. 1999 Jul-Aug;46(28):2621-4.

PMID:
10522052
25.

DNA methylation analysis using bisulfite treatment and PCR-single-strand conformation polymorphism in colorectal cancer showing microsatellite instability.

Maekawa M, Sugano K, Kashiwabara H, Ushiama M, Fujita S, Yoshimori M, Kakizoe T.

Biochem Biophys Res Commun. 1999 Sep 7;262(3):671-6.

PMID:
10471384
26.

Prognosis of advanced pancreatic cancer patients with reference to calorie intake.

Okusaka T, Okada S, Ishii H, Ikeda M, Kosakamoto H, Yoshimori M.

Nutr Cancer. 1998;32(1):55-8.

PMID:
9824858
27.

Undifferentiated carcinoma of the liver with neuroendocrine features: a case report.

Nakasuka H, Okada S, Okusaka T, Ishii H, Ikeda M, Ito R, Kosakamoto H, Yoshimori M, Nakanishi Y, Sakamoto M.

Jpn J Clin Oncol. 1998 Jun;28(6):401-4.

PMID:
9730157
28.

Past exposure to hepatitis B virus as a risk factor for hepatocellular carcinoma in patients with chronic liver disease.

Okada S, Sato T, Okusaka T, Ishii H, Ikeda M, Nakasuka H, Kosakamoto H, Yoshimori M, Wakabayashi K.

Br J Cancer. 1998 Jun;77(11):2028-31.

29.

Transarterial chemotherapy with zinostatin stimalamer for hepatocellular carcinoma.

Okusaka T, Okada S, Ishii H, Ikeda M, Nakasuka H, Nagahama H, Iwata R, Furukawa H, Takayasu K, Nakanishi Y, Sakamoto M, Hirohashi S, Yoshimori M.

Oncology. 1998 Jul-Aug;55(4):276-83.

PMID:
9663415
30.

Needle tract implantation of hepatocellular carcinoma after percutaneous ethanol injection.

Ishii H, Okada S, Okusaka T, Yoshimori M, Nakasuka H, Shimada K, Yamasaki S, Nakanishi Y, Sakamoto M.

Cancer. 1998 May 1;82(9):1638-42.

PMID:
9576282
31.

Pancreatic cancer: medical aspects.

Okada S, Yoshimori M, Kakizoe T.

Pancreas. 1998 Apr;16(3):349-54. Review.

PMID:
9548678
32.

Elevated serum interleukin-6 levels in patients with pancreatic cancer.

Okada S, Okusaka T, Ishii H, Kyogoku A, Yoshimori M, Kajimura N, Yamaguchi K, Kakizoe T.

Jpn J Clin Oncol. 1998 Jan;28(1):12-5.

PMID:
9491135
33.

Hepatocellular carcinoma with gastrointestinal hemorrhage caused by direct tumor invasion to the duodenum.

Okusaka T, Okada S, Ishii H, Nagahama H, Yoshimori M, Yamasaki S, Takayasu K, Kakizoe T, Ochiai A, Shimoda T.

Jpn J Clin Oncol. 1997 Oct;27(5):343-5.

PMID:
9390214
34.

Predictive factors for tumor response to systemic chemotherapy in patients with hepatocellular carcinoma.

Nagahama H, Okada S, Okusaka T, Ishii H, Ikeda M, Nakasuka H, Yoshimori M.

Jpn J Clin Oncol. 1997 Oct;27(5):321-4.

PMID:
9390209
35.

Protracted 5-fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma.

Ishii H, Okada S, Tokuuye K, Nose H, Okusaka T, Yoshimori M, Nagahama H, Sumi M, Kagami Y, Ikeda H.

Cancer. 1997 Apr 15;79(8):1516-20.

PMID:
9118032
36.

Evidence for increased somatic cell mutations in patients with hepatocellular carcinoma.

Okada S, Ishii H, Nose H, Okusaka T, Kyogoku A, Yoshimori M, Wakabayashi K.

Carcinogenesis. 1997 Feb;18(2):445-9.

PMID:
9054641
37.

Prognosis of hepatocellular carcinoma patients with extrahepatic metastases.

Okusaka T, Okada S, Ishii H, Nose H, Nagahama H, Nakasuka H, Ikeda K, Yoshimori M.

Hepatogastroenterology. 1997 Jan-Feb;44(13):251-7.

PMID:
9058154
38.

Effect of heavy alcohol intake on long-term results after curative resection of hepatitis C virus-related hepatocellular carcinoma.

Okada S, Ishii H, Nose H, Okusaka T, Kyogoku A, Yoshimori M, Shimada K, Yamamoto J, Kosuge T, Yamasaki S, Sakamoto M, Hirohashi S.

Jpn J Cancer Res. 1996 Aug;87(8):867-73.

39.

Predictive factors for recurrence after percutaneous ethanol injection for solitary hepatocellular carcinoma.

Ishii H, Okada S, Nose H, Okusaka T, Nagahama H, Nakayama H, Nakasuka H, Yoshimori M.

Hepatogastroenterology. 1996 Jul-Aug;43(10):938-43.

PMID:
8884317
40.

The prognosis of patients with hepatocellular carcinoma of multicentric origin.

Okusaka T, Okada S, Nose H, Ishii H, Nakasuka H, Nakayama H, Nagahama H, Yoshimori M, Shimada K, Yamamoto J, Takayama T, Kosuge T, Yamasaki S, Sakamoto M, Hirohashi S.

Hepatogastroenterology. 1996 Jul-Aug;43(10):919-25.

PMID:
8884314
41.

Effect of percutaneous ethanol injection for postoperative recurrence of hepatocellular carcinoma in combination with transcatheter arterial embolization.

Ishii H, Okada S, Sato T, Nose H, Okusaka T, Yoshimori M, Takayasu K, Takayama T, Kosuge T, Yamasaki S.

Hepatogastroenterology. 1996 May-Jun;43(9):644-50.

PMID:
8799409
42.

Local recurrence of hepatocellular carcinoma after percutaneous ethanol injection.

Ishii H, Okada S, Nose H, Okusaka T, Yoshimori M, Takayama T, Kosuge T, Yamasaki S, Sakamoto M, Hirohashi S.

Cancer. 1996 May 1;77(9):1792-6.

PMID:
8646676
43.

Prognostic factors in patients with advanced pancreatic cancer treated with systemic chemotherapy.

Ishii H, Okada S, Nose H, Yoshimori M, Aoki K, Okusaka T.

Pancreas. 1996 Apr;12(3):267-71.

PMID:
8830333
44.

Influence of alcohol abuse on recurrence after curative resection of hepatocellular carcinoma.

Okada S, Ishii H, Nose H, Yoshimori M, Shimada K, Yamamoto J, Takayama T, Kosuge T, Yamasaki S, Sakamoto M, et al.

Hepatogastroenterology. 1995 Nov-Dec;42(6):944-9.

PMID:
8847050
45.

Intratumoral DNA heterogeneity of small hepatocellular carcinoma.

Okada S, Ishii H, Nose H, Okusaka T, Kyogoku A, Yoshimori M, Sakamoto M, Hirohashi S.

Cancer. 1995 Jan 15;75(2):444-50.

PMID:
7812914
46.

A phase II study of cisplatin in patients with biliary tract carcinoma.

Okada S, Ishii H, Nose H, Yoshimori M, Okusaka T, Aoki K, Iwasaki M, Furuse J, Yoshino M.

Oncology. 1994 Nov-Dec;51(6):515-7.

PMID:
7970496
47.

Radiotherapy for hepatocellular carcinoma: clinicopathological study of seven autopsy cases.

Aoki K, Okazaki N, Okada S, Nose H, Yoshimori M, Akine Y, Egawa S, Sakamoto M, Hirohashi S.

Hepatogastroenterology. 1994 Oct;41(5):427-31.

PMID:
7851850
48.

Accuracy of computed tomography in determining pancreatic cancer tumor size.

Aoki K, Okada S, Moriyama N, Ishii H, Nose H, Yoshimori M, Kosuge T, Ozaki H, Wakao F, Takayasu K, et al.

Jpn J Clin Oncol. 1994 Apr;24(2):85-7.

PMID:
8158861
49.

Leiomyosarcoma of the pancreas: report of a case diagnosed by fine needle aspiration biopsy.

Ishii H, Okada S, Okazaki N, Nose H, Yoshimori M, Aoki K, Tsuda H, Hirohashi S.

Jpn J Clin Oncol. 1994 Feb;24(1):42-5.

PMID:
8126920
50.

Liver abscess after percutaneous ethanol injection (PEI) therapy for hepatocellular carcinoma. A case report.

Okada S, Aoki K, Okazaki N, Nose H, Yoshimori M, Shimada K, Yamamoto J, Takayama T, Kosuge T, Yamasaki S, et al.

Hepatogastroenterology. 1993 Oct;40(5):496-8.

PMID:
8270243

Supplemental Content

Loading ...
Support Center